Clinical Trial

Bladder Perfusion of Plasma-Activated Saline for Bladder Cancer

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 9, 2025 (before its estimated February 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This preliminary clinical study evaluates the safety and initial efficacy of a novel therapy called Plasma-Activated Saline Solution (PASS) for bladder cancer patients. The study involves a one-week course of PASS administered via bladder infusion in five pre-surgical patients, using imaging and pathology analyses to assess tumor shrinkage and cancer cell death, while closely monitoring for any adverse reactions to explore the therapy's future potential.
Trial Details
NCT Number NCT07272603
Lead Sponsor Qilu Hospital of Shandong University
Conditions Bladder (Urothelial, Transitional Cell) Cancer
Enrollment 5 participants
Start Date 2025-12-15
Primary Completion 2026-02-15 (estimated)
Study Completion 2026-02-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-09